Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02397278 |
Recruitment Status :
Completed
First Posted : March 24, 2015
Results First Posted : August 5, 2021
Last Update Posted : August 5, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteochondritis Dissecans | Drug: Platelet rich plasma (PRP) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 15 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Arm 1- Conservative Treatment Arm 2- PRP Injections |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee: Does it Help? A Clinical and Magnetic Resonance Imaging (MRI) Study. |
Actual Study Start Date : | March 2015 |
Actual Primary Completion Date : | January 8, 2020 |
Actual Study Completion Date : | January 8, 2020 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Platelet rich plasma (PRP)
Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
|
Drug: Platelet rich plasma (PRP)
Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
Other Name: autologous PRP |
No Intervention: Conventional therapy
Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
|
- Greater Cartilage Healing Measured by Glycosaminoglycan Content on dGEMRIC MRI [ Time Frame: 6 months ]Measured by dGEMRIC MRI
- Improvement in Pain, Performance and Overall Function: IKDC [ Time Frame: Baseline, 6 months, 12 months ]Measured by the Pediatric IKDC survey results. The International Knee Documentation Committee questionnaire measures knee function, Scores range from 1-100, with higher scores indicating a better outcome.
- Improvement in Pain, Performance and Overall Function: KOOS, Baseline [ Time Frame: Baseline ]Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
- Improvement in Pain, Performance and Overall Function: KOOS, 6 Months [ Time Frame: 6 Months ]Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
- Improvement in Pain, Performance and Overall Function: KOOS, 12 Months [ Time Frame: 12 Months ]Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
- dGemric MRI Findings Correlate With Measures of Functional Recovery and Symptom Reduction. [ Time Frame: 6 months ]Measured by the results of the dGEMRIC MRI and the IKDC and KOOS survey results

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 10 Years to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female age 10 - 17 inclusive with open physis confirmed by MRI
- Documented symptomatic stable juvenile osteochondritis dissecans of the knee based on MRI without changes of osteoarthritis and no prior history of knee surgery.
- The patient must be able to hold still without sedation for approximately 1 hour and must pass MRI screening evaluation for retained metal.
- Patients with Di Paola stage 1 or 2 lesions
Exclusion Criteria:
- Patients with polyarticular disease.
- Patients with blood disorders (Blood disorders (thrombopathy, thrombocytopenia, anemia with hemoglobin <9g/dL). Only those patients with a positive history of blood disorders will have a Complete Blood Count (CBC) performed a week prior to inclusion in the study.
- Patients who had intra-articular treatment with steroids within 3 months
- Patients who are pregnant or nursing at the time of consent.
- Patients with inflammatory arthritic conditions (e.g. rheumatoid arthritis)
- Non-English speaking patients. (Scores used for evaluation have not been validated in Spanish)
- Patients who had previous knee surgery
- Additional disabilities in any of the lower limbs that would interfere with any of the clinical assessments.
- Chronic use of NSAID (defined as taking non-steroidal anti-inflammatory drug) regularly every week for the last 6 months), steroids or chemotherapy drugs
- Treatment with NSAIDs within 15 days prior to randomization in this study
- Patients with a BMI over 30. Due to the fact that this study utilizes an injection technique which may be inaccurate in obese subjects.
- Patients with a prolongation of bleeding time, e.g. those receiving anticoagulant drug therapy
- Patients with a contraindication to MRI including: patients with cardiac pacemaker or non-approved intracranial vascular clip, and those with orthopedic hardware as the resulting artifact can complicate interpretation
- Patients with acute or chronic renal failure
- Patients with a previous anaphylactic reaction to gadolinium enhanced MRI.
- Patients with Di Paola stage 3 or 4 lesions

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02397278
United States, Colorado | |
Children's Hospital Colorado | |
Aurora, Colorado, United States, 80045 |
Principal Investigator: | Michael Fadell, MD | Children's Hospital Colorado |
Documents provided by University of Colorado, Denver:
Responsible Party: | University of Colorado, Denver |
ClinicalTrials.gov Identifier: | NCT02397278 |
Other Study ID Numbers: |
13-2797 |
First Posted: | March 24, 2015 Key Record Dates |
Results First Posted: | August 5, 2021 |
Last Update Posted: | August 5, 2021 |
Last Verified: | July 2021 |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Osteochondritis Osteochondritis Dissecans Osteochondrosis Bone Diseases |
Musculoskeletal Diseases Cartilage Diseases Connective Tissue Diseases |